Study guide
4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia
Board Certified Ambulatory Care Pharmacist BCACP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Patient Care Process
1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence
2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia
2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons
3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation
3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
4 Chapter 4: Endocrine & Metabolic Disorders
4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing
5 Chapter 5: Respiratory Care & Pulmonology
5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling
6 Chapter 6: Renal, Urological & Reproductive Health
6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity
7 Chapter 7: Neuropsychiatry & Behavioral Health
7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders
8 Chapter 8: Pain Management & Rheumatology
8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy
9 Chapter 9: Infectious Diseases & Immunizations
9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations
10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety
10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety
11 Chapter 11: Biostatistics, Study Design & Literature Evaluation
11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics
12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery
12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest
4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia
Key Takeaways Explain This Topic AI
Basal insulin is initiated at 10 units/day or 0.1–0.2 units/kg/day and titrated by 2 units every 3 days to achieve fasting plasma glucose 80–130 mg/dL; postprandial excursions warrant stepwise addition of prandial insulin (basal-plus to basal-bolus) or GLP-1 RA combination.
Second-generation ultra-long basal insulins (degludec U-100/U-200, glargine U-300) demonstrate flat, peakless pharmacokinetic profiles extending beyond 24 to 42 hours, significantly reducing nocturnal hypoglycemia compared to first-generation glargine U-100 or detemir.
Intensive prandial management utilizes the 500 Rule for Insulin-to-Carbohydrate Ratio (ICR = 500 / TDD) and the 1800/1500 Rule for Correction Factor / Insulin Sensitivity Factor (ISF = 1800 / TDD for rapid-acting, 1500 / TDD for regular insulin).
Ambulatory Glucose Profile (AGP) core CGM metrics require Time in Range (TIR 70–180 mg/dL) >70% (>50% in older/high-risk adults), Time Below Range (TBR <70 mg/dL) <4%, and TBR <54 mg/dL <1%, with Glucose Management Indicator (GMI) reflecting estimated average A1C.
Acute hypoglycemia is staged as Level 1 (<70 mg/dL), Level 2 (<54 mg/dL), and Level 3 (severe cognitive impairment); conscious patients apply the Rule of 15, while unconscious/incapacitated patients receive emergency glucagon (nasal Baqsimi 3 mg, subcutaneous auto-injectors Gvoke or Zegalogue).
Last updated: September 2026
4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia
BCACP Exam Anchor: Advanced diabetes management requires precision in insulin pharmacokinetic profiles, mathematical mastery of intensive basal-bolus calculations (Total Daily Dose, Insulin-to-Carbohydrate Ratio, and Correction Sensitivity Factor), expert interpretation of standardized Continuous Glucose Monitoring (CGM) Ambulatory Glucose Profiles, and immediate execution of modern hypoglycemia protocols.
1. Insulin Formulations & Pharmacokinetic Profiles
Exogenous insulin regimens are designed to replicate physiologic pancreatic insulin secretion: constant, low-level basal secretion suppressing hepatic gluconeogenesis overnight and between meals, combined with rapid prandial spikes in response to ingested carbohydrates.
Insulin Category Formulations & Brand Names Onset Peak Effective Duration Clinical Nuances & Pearls
Ultra-Rapid Acting Lispro-aabc (Lyumjev) ; Aspart-fast (Fiasp) 1–5 min 45–60 min 3–5 hours Co-formulated with excipients (citrate/treprostinil or niacinamide) to accelerate vascular permeability. Administer at start of meal or up to 20 min after.
Rapid-Acting Lispro (Humalog U-100/U-200) ; Aspart (Novolog) ; Glulisine (Apidra) 10–20 min 1–2 hours 3–5 hours Standard prandial bolus. Administer 10–15 min prior to meal. Ideal for pump therapy (CSII).
Short-Acting (Regular) Regular Human (Humulin R, Novolin R U-100) ; U-500 Regular (Humulin R U-500) 30–60 min; (U-500: 30 min) 2–4 hours; (U-500: 4–8 hr) 6–8 hours; (U-500: 12–24 hr) U-100 regular given 30 min before meals. U-500 Regular acts as both basal and bolus in severe insulin resistance (TDD >200 units/day); dose with dedicated U-500 syringe or pen.
Intermediate-Acting NPH (Humulin N, Novolin N) 1–2 hours 4–8 hours 14–18 hours Cloudy suspension (requires rolling/mixing). Erratic absorption; high risk of nocturnal hypoglycemia if given at bedtime.
Long-Acting Basal (1st Gen) Glargine U-100 (Lantus, Basaglar, Semglee) ; Detemir (Levemir) 1–2 hours Relatively peakless 20–24 hours; (Detemir: 14–20 hr) Acidic pH (cannot mix in same syringe with other insulins). Detemir often requires BID dosing at low doses (<0.4 units/kg/day).
Ultra-Long Basal (2nd Gen) Degludec U-100/U-200 (Tresiba) ; Glargine U-300 (Toujeo SoloStar/Max) 30–90 min Truly flat / peakless >42 hours (Degludec); ~36 hours (Glargine U-300) Forms multi-hexamer subcutaneous depots. Lowest nocturnal hypoglycemia risk. Degludec offers flexible day-to-day administration timing (min 8 hours between doses). Glargine U-300 requires ~10–15% higher dose when converting from U-100.
2. Regimen Design & Stepwise Intensification in T2D
When non-insulin agents (metformin, SGLT2i, GLP-1 RA) fail to achieve glycemic targets, insulin therapy is intensified in a stepwise manner: Non-Insulin Therapies (GLP-1 RA / SGLT2i / Metformin)
- │
- ▼
- Initiate Basal Insulin Monotherapy
- 10 units/day OR 0.1-0.2 units/kg/day once daily
- │
- ▼
- Titrate Basal Dose Treat-to-Target
- Increase by 2 units every 3 days to FPG 80-130 mg/dL
- │
- ▼
- Check for "Overbasalization"
- (Basal dose >0.5 units/kg/day, high bedtime-to-morning
- glucose differential, high glucose variability, hypoglycemia)
- │
- ┌─────────────────────────────┴─────────────────────────────┐
- ▼ ▼
- Add GLP-1 RA (if not already used) Intensify to Prandial Bolus Therapy
- Fixed-Ratio Combinations (iGlarLixi / iDegLira) 1. Basal-Plus: Add 4 units or 10% basal
- High glycemic efficacy with weight/hypo mitigation prior to largest meal of the day
- 2. Basal-Bolus: Add prandial before 2-3 meals
- Clinical Overbasalization Signals
Escalating basal insulin beyond 0.5 units/kg/day without addressing postprandial glucose surges leads to clinical overbasalization. Warning signs include:
Basal insulin dose > 0.5 units/kg/day >0.5\text{ units/kg/day} > 0.5 units/kg/day (approaching > 0.7 – 1.0 units/kg/day >0.7–1.0\text{ units/kg/day} > 0.7–1.0 units/kg/day ).
Bedtime-to-morning glucose differential > 50 mg/dL >50\text{ mg/dL} > 50 mg/dL (bedtime glucose significantly higher than fasting morning glucose).
Frequent hypoglycemia alongside persistent A1C elevation.
High glycemic variability.
Action: Stop escalating basal insulin. Initiate prandial insulin (Basal-Plus or Basal-Bolus) or add a GLP-1 receptor agonist.
3. Advanced Intensive Insulin Calculations
In patients managed on intensive basal-bolus therapy or continuous subcutaneous insulin infusion (CSII insulin pump), pharmacists must precisely calculate prandial coverage and correction boluses:
Total Daily Dose (TDD) Estimation
Initial TDD Estimate: 0.4 to 0.6 units/kg/day 0.4\text{ to } 0.6\text{ units/kg/day} 0.4 to 0.6 units/kg/day (use 0.1 – 0.3 units/kg/day 0.1–0.3\text{ units/kg/day} 0.1–0.3 units/kg/day for frail/elderly/CKD; 0.6 – 1.0 + units/kg/day 0.6–1.0+\text{ units/kg/day} 0.6–1.0 + units/kg/day in severe insulin resistance/obesity).
Basal / Bolus Split: Typically 50% Basal and 50% Prandial (divided equally among 3 meals).
Insulin-to-Carbohydrate Ratio (ICR) — The 500 Rule
Represents the grams of carbohydrate covered by 1 unit of rapid-acting insulin: ICR (g carb / 1 unit rapid-acting insulin) = 500 TDD \text{ICR (g carb / 1 unit rapid-acting insulin)} = \frac{500}{\text{TDD}} ICR (g carb / 1 unit rapid-acting insulin) = TDD 500
(Note: For regular insulin, use the 450 Rule: 450 / TDD 450 / \text{TDD} 450/ TDD ) .
Insulin Sensitivity Factor (ISF) / Correction Factor (CF) — The 1800 Rule
Represents the anticipated drop in blood glucose (mg/dL) produced by 1 unit of rapid-acting insulin: ISF (mg/dL per 1 unit rapid-acting insulin) = 1800 TDD \text{ISF (mg/dL per 1 unit rapid-acting insulin)} = \frac{1800}{\text{TDD}} ISF (mg/dL per 1 unit rapid-acting insulin) = TDD 1800
(Note: For regular insulin, use the 1500 Rule: 1500 / TDD 1500 / \text{TDD} 1500/ TDD ) .
Comprehensive Bolus Dose Calculation Formula Total Mealtime Bolus = ( Carbohydrate Ingested (g) ICR ) + ( Current Blood Glucose − Target Blood Glucose ISF ) \text{Total Mealtime Bolus} = \left( \frac{\text{Carbohydrate Ingested (g)}}{\text{ICR}} \right) + \left( \frac{\text{Current Blood Glucose} - \text{Target Blood Glucose}}{\text{ISF}} \right) Total Mealtime Bolus = ( ICR Carbohydrate Ingested (g) ) + ( ISF Current Blood Glucose − Target Blood Glucose )
4. Continuous Glucose Monitoring (CGM) & AGP Interpretation
Standardized Continuous Glucose Monitoring provides an Ambulatory Glucose Profile (AGP) that reveals dynamic glycemic patterns, glycemic variability, and occult hypoglycemia.
CGM Metric Target for Standard Adults (T1D & T2D) Target for Older / Frail / High-Risk Adults Clinical Action if Unmet
Time in Range (TIR: 70–180 mg/dL) > 70% (>16 hours 48 minutes/day) > 50% (>12 hours/day) Every 10% increase in TIR reduces microalbuminuria by ~40% and retinopathy by ~35%.
Time Below Range (TBR Level 1: 54–69 mg/dL) < 4.0% (<1 hour/day) < 1.0% (<15 minutes/day) Primary Clinical Priority: Always address and eliminate hypoglycemia before addressing hyperglycemia.
Time Below Range (TBR Level 2: <54 mg/dL) < 1.0% (<15 minutes/day) < 1.0% (<15 minutes/day) Urgent de-escalation of insulin/sulfonylurea therapy required.
Time Above Range (TAR Level 1: 181–250 mg/dL) < 25.0% (<6 hours/day) < 50.0% (Combined TAR) Adjust prandial/basal dosing or add non-insulin organ-protective agents.
Time Above Range (TAR Level 2: >250 mg/dL) < 5.0% (<1 hour 12 minutes/day) < 10.0% Optimize postprandial bolus timing and ICR.
Coefficient of Variation (%CV) ≤ 36 % \le 36\% ≤ 36% ≤ 36 % \le 36\% ≤ 36% % CV = ( SD / Mean Glucose ) × 100 \%\text{CV} = (\text{SD} / \text{Mean Glucose}) \times 100 % CV = ( SD / Mean Glucose ) × 100 . % CV > 36 % \%\text{CV} > 36\% % CV > 36% indicates high glycemic instability and elevated hypoglycemia risk.
Glucose Management Indicator (GMI) Correlates with laboratory A1C Correlates with laboratory A1C Calculated from mean CGM glucose over ≥ 14 \ge 14 ≥ 14 days: GMI (%) = 3.31 + ( 0.02392 × Mean Glucose [mg/dL] ) \text{GMI (\%)} = 3.31 + (0.02392 \times \text{Mean Glucose [mg/dL]}) GMI (%) = 3.31 + ( 0.02392 × Mean Glucose [mg/dL] ) .
- 5. Hypoglycemia Staging & Emergency Glucagon Management
- ADA Classification of Hypoglycemia
Level 1 (Mild / Alert): Measurable glucose 54 to 69 mg/dL 54\text{ to } 69\text{ mg/dL} 54 to 69 mg/dL . Patient is fully conscious and symptomatic (tremor, diaphoresis, palpitations, hunger).
Level 2 (Moderate / Clinically Significant): Glucose < 54 mg/dL <54\text{ mg/dL} < 54 mg/dL . Immediate neuroglycopenic risk; triggers acute counter-regulatory hormone response.
Level 3 (Severe): Characterized by severe cognitive or physical impairment requiring external third-party assistance for recovery, regardless of the numeric glucose reading.
- Acute Treatment Protocols Suspected Hypoglycemia
- │
- ▼
- Check Blood Glucose
- │
- ┌────────────────────────┴────────────────────────┐
- ▼ ▼
- Conscious & Able to Swallow Unconscious / Incapacitated / Seizing
- (Level 1 or Level 2) (Level 3)
- │ │
- ▼ ▼
- "Rule of 15" Emergency Glucagon Administration
- 1. Ingest 15-20g fast-acting carbs 1. Nasal Baqsimi (3 mg powder in 1 nostril) OR
- (4 oz juice/soda, 4 glucose tabs, 2. SubQ Gvoke (1 mg autoinjector) OR
- 1 tube glucose gel, 8 oz skim milk) 3. SubQ Zegalogue (0.6 mg autoinjector)
- 2. Rest and wait 15 minutes 4. Call 911 immediately
- 3. Recheck blood glucose 5. Turn patient on side (recovery position)
- 4. If BG <70 mg/dL → Repeat 15g carbs 6. Feed carbohydrate meal once awake
- 5. If BG ≥70 mg/dL → Eat meal/snack
- Modern Ready-to-Use Emergency Glucagon Formulations
Historical reconstituted glucagon kits (vial and syringe requiring multi-step mixing) have high failure rates during emergency crises. Modern stable formulations are preferred:
Nasal Glucagon (Baqsimi 3 mg): Single-use nasal powder device. Passively absorbed across nasal mucosa; does not require inhalation or active sniffing. Effective even in patients with rhinitis or nasal congestion.
Liquid Stable Glucagon Autoinjector / Prefilled Syringe (Gvoke HypoPen 1 mg for adults, 0.5 mg for pediatrics): Ready-to-inject room-temperature subcutaneous injection (thigh, abdomen, outer arm).
Dasiglucagon Autoinjector / Prefilled Syringe (Zegalogue 0.6 mg SubQ): Fast-acting synthetic peptide glucagon receptor agonist with rapid glycemic recovery (median time 10 minutes).